NASDAQ:IMV - IMV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.41
  • Forecasted Upside: 214.39 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.07 (-3.91%)

This chart shows the closing price for IMV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IMV Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMV

Analyst Price Target is $5.41
▲ +214.39% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for IMV in the last 3 months. The average price target is $5.41, with a high forecast of $13.00 and a low forecast of $1.38. The average price target represents a 214.39% upside from the last price of $1.72.

This chart shows the closing price for IMV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in IMV. This rating has held steady since May 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2021Wells Fargo & CompanyInitiated CoverageOverweight$1.38High
7/16/2021Raymond JamesLower Price TargetMarket Perform$3.00 ➝ $2.00High
5/13/2021Raymond JamesSet Price TargetMarket Perform$3.00Low
3/18/2021Leede Jones GabReiterated RatingSpeculative BuyHigh
3/18/2021National BanksharesLower Price TargetSector Perform$7.00 ➝ $5.25Medium
3/18/2021Raymond JamesReiterated RatingMarket Perform$3.00Medium
12/29/2020Raymond JamesSet Price TargetMarket Perform$3.00N/A
12/4/2020Raymond JamesSet Price TargetMarket Perform$3.00Low
11/11/2020Raymond JamesSet Price TargetMarket Perform$3.00Medium
11/5/2020Raymond JamesSet Price TargetMarket Perform$3.00Medium
10/9/2020Raymond JamesSet Price TargetMarket Perform$3.00Medium
8/12/2020HC WainwrightReiterated RatingBuy$13.00High
8/7/2020National Bank FinancialDowngradeOutperform Market Weight ➝ Sector Perform Market WeightMedium
8/6/2020Raymond JamesSet Price TargetMarket Perform$3.00Low
7/22/2020HC WainwrightReiterated RatingBuy$13.00Low
7/21/2020Industrial Alliance SecuritiesInitiated CoverageBuy$10.00Low
7/15/2020Raymond JamesSet Price TargetMarket Perform$3.00High
7/14/2020Wells Fargo & CompanyBoost Price Target$8.50 ➝ $11.00N/A
6/1/2020Raymond JamesSet Price TargetMarket Perform$3.00High
6/1/2020HC WainwrightReiterated RatingBuy$13.00High
5/25/2020Echelon Wealth PartnersReiterated RatingBuy$9.00Medium
5/19/2020Raymond JamesSet Price TargetMarket Perform$3.00High
5/18/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$2.50 ➝ $8.50High
5/15/2020HC WainwrightBoost Price TargetBuy$11.50 ➝ $13.00High
3/31/2020HC WainwrightReiterated RatingBuy$11.50High
3/31/2020B. RileyDowngradeBuy ➝ Neutral$7.00 ➝ $3.00High
3/31/2020Raymond JamesSet Price TargetMarket Perform$3.00High
3/18/2020HC WainwrightReiterated RatingBuy$11.50High
3/18/2020Raymond JamesDowngradeOutperform ➝ Market Perform$4.50 ➝ $3.00High
2/27/2020Echelon Wealth PartnersReiterated RatingBuy$9.00High
2/26/2020Raymond JamesLower Price TargetOutperform$10.00 ➝ $4.50Medium
2/25/2020HC WainwrightReiterated RatingBuy$11.50High
2/25/2020B. RileyReiterated RatingBuy$11.00High
2/25/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$3.50High
2/10/2020HC WainwrightReiterated RatingBuy$11.50Medium
2/6/2020B. RileyReiterated RatingBuy$11.00Medium
1/28/2020BTIG ResearchInitiated CoverageBuy$8.00High
1/21/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.00High
12/10/2019B. RileyReiterated RatingBuy$11.00High
12/10/2019Raymond JamesSet Price TargetOutperform$10.00High
12/9/2019HC WainwrightReiterated RatingBuy$11.50Low
11/25/2019OppenheimerInitiated CoverageOutperformHigh
11/12/2019Echelon Wealth PartnersReiterated RatingBuy$12.25Medium
11/11/2019HC WainwrightReiterated RatingBuy$11.50High
11/7/2019Raymond JamesSet Price TargetOutperform$10.00Low
10/28/2019Wells Fargo & CompanyInitiated CoverageMarket PerformLow
10/1/2019Raymond JamesSet Price TargetOutperform$10.00Low
9/30/2019HC WainwrightSet Price TargetBuy$11.50High
8/12/2019Raymond JamesSet Price TargetOutperform$10.00Low
6/13/2019Raymond JamesSet Price TargetOutperform$10.00Medium
6/12/2019HC WainwrightReiterated RatingBuy$11.50Medium
6/4/2019Echelon Wealth PartnersReiterated RatingBuyMedium
6/3/2019Raymond JamesSet Price TargetOutperform$10.00Medium
6/3/2019HC WainwrightReiterated RatingBuy$11.50High
5/29/2019B. RileyInitiated CoverageBuy ➝ Buy$11.00 ➝ $11.00High
5/13/2019Raymond JamesSet Price TargetMarket Perform$10.00Medium
5/10/2019HC WainwrightSet Price TargetBuy$12.00High
3/25/2019Raymond JamesSet Price TargetOutperform$10.00Low
3/25/2019HC WainwrightInitiated CoverageBuy ➝ Buy$11.50Medium
1/30/2019Raymond JamesSet Price TargetOutperform$10.00Low
12/14/2018Raymond JamesSet Price TargetOutperform$10.00Low
11/22/2018Raymond JamesSet Price TargetOutperform$10.00High
6/19/2018Dawson JamesReiterated RatingBuyMedium
6/4/2018National Bank FinancialReiterated RatingOutperform Market WeightMedium
(Data available from 8/2/2016 forward)
IMV logo
IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Read More

Today's Range

Now: $1.72
Low: $1.66
High: $1.77

50 Day Range

MA: $2.10
Low: $1.35
High: $2.45

52 Week Range

Now: $1.72
Low: $1.31
High: $5.73


831,499 shs

Average Volume

882,029 shs

Market Capitalization

$141.18 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of IMV?

The following Wall Street sell-side analysts have issued research reports on IMV in the last twelve months: HC Wainwright, Leede Jones Gab, National Bank Financial, National Bankshares, Inc., Raymond James, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for IMV.

What is the current price target for IMV?

4 Wall Street analysts have set twelve-month price targets for IMV in the last year. Their average twelve-month price target is $5.41, suggesting a possible upside of 214.4%. HC Wainwright has the highest price target set, predicting IMV will reach $13.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $1.38 for IMV in the next year.
View the latest price targets for IMV.

What is the current consensus analyst rating for IMV?

IMV currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IMV, but not buy more shares or sell existing shares.
View the latest ratings for IMV.

What other companies compete with IMV?

How do I contact IMV's investor relations team?

IMV's physical mailing address is 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4. The company's listed phone number is 902 492 1819 and its investor relations email address is [email protected] The official website for IMV is